KOD - Kodiak Sciences Inc.

-

$undefined

N/A

(N/A)

Kodiak Sciences Inc. NasdaqGM:KOD Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Location: 1200 Page Mill Road, Palo Alto, CA, 94304, United States | Website: https://kodiak.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

116.7M

Cash

138.9M

Avg Qtr Burn

-26.7M

Short % of Float

10.40%

Insider Ownership

5.52%

Institutional Own.

81.86%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
KSI-501 (anti-VEGF & IL-6) Details
Eye disease , Wet age-related macular degeneration

Phase 3

Data readout

Tarcocimab (KSI-301) (anti-VEGF) Details
Non-proliferative diabetic retinopathy

Phase 3

Data readout

KSI-101 Details
Eye disease

Phase 2b

Data readout

KSI-501 (anti-VEGF & IL-6) Details
Diabetic macular edema, Eye disease

Phase 1

Update

Failed

Discontinued

Tarcocimab (KSI-301) Details
Retinal vein occlusion

Failed

Discontinued

Tarcocimab (KSI-301) Details
Wet age-related macular degeneration

Failed

Discontinued